DrugPatentWatch Database Preview
Drugs in Development Information for Tivantinib
What is the drug development status for Tivantinib?
Tivantinib is an investigational drug.
There have been 27 clinical trials for Tivantinib.
The most recent clinical trial was a Phase 2 trial, which was initiated on November 1st 2010.
The most common disease conditions in clinical trials are Carcinoma, Lung Neoplasms, and Carcinoma, Hepatocellular. The leading clinical trial sponsors are National Cancer Institute (NCI), Daiichi Sankyo Inc., and ArQule.
There are nineteen US patents protecting this investigational drug and one hundred and thirty-six international patents.
Summary for Tivantinib
| US Patents | 19 |
| International Patents | 136 |
| US Patent Applications | 34 |
| WIPO Patent Applications | 16 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2010-11-01) |
| Vendors | 51 |
Recent Clinical Trials for Tivantinib
| Title | Sponsor | Phase |
|---|---|---|
| TIvantinib as Maintenance Treatment in Extended Small-cell Lung Cancer (TIMES) | Istituto Oncologico Veneto IRCCS | Phase 2 |
| Pharmacokinetics of Tivantinib in Subjects With Advanced Solid Tumors and Hepatic Impairment | Medpace, Inc. | Phase 1 |
| Pharmacokinetics of Tivantinib in Subjects With Advanced Solid Tumors and Hepatic Impairment | Daiichi Sankyo Inc. | Phase 1 |
Clinical Trial Summary for Tivantinib
Top disease conditions for Tivantinib
Top clinical trial sponsors for Tivantinib
US Patents for Tivantinib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Tivantinib | Start Trial | Combination therapy using c-Met inhibitor and IGF-1R inhibitor for c-Met inhibitor resistant cancers | SAMSUNG ELECTRONICS CO., LTD. (Suwon-si, KR) YONSEI UNIVERSITY, UNIVERSITY-INDUSTRY FOUNDATION (UIF) (Seoul, KR) | Start Trial |
| Tivantinib | Start Trial | Compositions and methods for treatment of cancer | ArQule, Inc. (Woburn, MA) | Start Trial |
| Tivantinib | Start Trial | Kinase inhibition models and their uses | ArQule, Inc. (Woburn, MA) | Start Trial |
| Tivantinib | Start Trial | Kinase inhibition models and their uses | ArQule, Inc. (Woburn, MA) | Start Trial |
| Tivantinib | Start Trial | Pyrrolidinone, pyrrolidine-2,5-dione, pyrrolidine and thiosuccinimide derivatives, compositions and methods for treatment of cancer | ArQule, Inc. (Woburn, MA) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Tivantinib
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Tivantinib | South Korea | 20160061200 | 2034-11-21 | Start Trial |
| Tivantinib | Austria | 486872 | 2025-02-09 | Start Trial |
| Tivantinib | Australia | 2006213890 | 2025-02-09 | Start Trial |
| Tivantinib | Brazil | PI0607240 | 2025-02-09 | Start Trial |
| Tivantinib | Canada | 2599611 | 2025-02-09 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
